GlassScriptPhysician profile
Jose Garcia
NPI 1093832974
$11,554.56
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,586 · 2020: $3,400 · 2021: $2,796 · 2022: $810 · 2023: $740 · 2024: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $963.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,774.01 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $1,761.69 | 2019-2024 | Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $1,275.74 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $764.25 | 2019-2022 | |
| Novo Nordisk INC | $593.38 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $531.76 | 2019-2023 | Mounjaro |
| Glaxosmithkline, LLC. | $465.35 | 2019-2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $459.62 | 2019-2020 | |
| Amgen INC. | $458.23 | 2019-2023 | Prolia, Evenity, Otezla |
| Abbott Laboratories | $392.94 | 2022-2024 | Amplatzer Amulet, Amplatzer Talisman, Perclose Prostyle |
| Abbvie INC. | $388.79 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $340.97 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $297.57 | 2019-2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $254.04 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $201.63 | 2019-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.